Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02609945 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
A Phase 1 study of Migraine, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT02609945 is a Phase 1 study of Migraine that has completed, run by Acorda Therapeutics. The registered enrollment target is 21 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02609945, a Phase 1 study of Migraine, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is the first study in humans with CVT-427 (zolmitriptan inhalation powder) and is designed to evaluate the safety, tolerability, and PK of single ascending doses of CVT-427 in adult healthy volunteers.
Conditions Studied
Interventions
- DRUG zolmitriptan
- DRUG CVT-427 (zolmitriptan inhalation powder),
Study Locations (2)
Florida
- Site 001 - Daytona Beach
Texas
- Site 002 - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02609945
The ClinicalTrials.gov registry entry for NCT02609945 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (94% lower). The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which zolmitriptan is the first listed.
NCT02609945 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT02609945 about?
NCT02609945 is a clinical study titled "Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults". This study is the first study in humans with CVT-427 (zolmitriptan inhalation powder) and is designed to evaluate the safety, tolerability, and PK of single ascending doses of CVT-427 in adult healthy volunteers.
What is the current status of trial NCT02609945?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2015-11. Estimated completion is 2016-04.
What conditions does trial NCT02609945 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT02609945?
The interventions under investigation include: zolmitriptan (DRUG), CVT-427 (zolmitriptan inhalation powder), (DRUG).
Who is sponsoring clinical trial NCT02609945?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02609945 being conducted?
This trial has 2 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
COMPLETED · Phase 1
-
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
COMPLETED · Phase 1
-
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
COMPLETED · Phase 1
-
A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants
COMPLETED · Phase 1
-
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
COMPLETED · Phase 1
-
Migraine Manager (R01)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.